ArticleScientific reports2026
Disease laterality independently predicts survival in stage IIIB cervical cancer in a prospective cohort study from Northeast India.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Laterality of disease involvement in cervical cancer-unilateral versus bilateral parametrium and hydronephrosis-may carry prognostic implications in stage IIIB cervical cancer. Prospective Indian data addressing this issue remains limited. To evaluate the impact of unilateral and bilateral disease involvement on treatment response in women with locally advanced cervical cancer. This prospective, single-centre study (2022-2024) included 216 women with FIGO stage IIIB cervical cancer. Demographic, clinical, and radiological characteristics were collected. Disease laterality was assessed for the parametrium and hydronephrosis. Treatment response was evaluated using RECIST 1.1 criteria. Unilateral parametrium involvement predominated 162 (75%), with bilateral involvement in 54 (25%). Hydronephrosis was absent in 135 (65.3%), unilateral in 63 (27.8%), and bilateral in 18 (6.9%). Complete response (CR) was observed in 180 (83.34%) of patients. CR rates were 144 (88.8%) for unilateral and 36 (66%) for bilateral parametrium groups (p < 0.05). CR rates were seen in 120 (88.8%) for no hydronephrosis, 51 (81%) for unilateral hydronephrosis and 9 (50%) for bilateral hydronephrosis, respectively (p < 0.05). Bilateral hydronephrosis was associated with poorer response trends with CR - 9 (50%). Unilateral disease predominated, but bilateral hydronephrosis was associated with inferior outcomes. Disease laterality should be considered a relevant prognostic factor in advanced cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.